These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1618257)

  • 1. Absence of interaction between tenoxicam and warfarin.
    Eichler HG; Jung M; Kyrle PA; Rotter M; Korn A
    Eur J Clin Pharmacol; 1992; 42(2):227-9. PubMed ID: 1618257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the interaction between lornoxicam and warfarin in healthy volunteers.
    Ravic M; Johnston A; Turner P; Ferber HP
    Hum Exp Toxicol; 1990 Nov; 9(6):413-4. PubMed ID: 2271233
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers.
    Day RO; Geisslinger G; Paull P; Williams KM
    Int J Clin Pharmacol Ther; 1995 May; 33(5):308-10. PubMed ID: 7655772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.
    Day RO; Geisslinger G; Paull P; Williams KM
    Br J Clin Pharmacol; 1994 Jan; 37(1):79-81. PubMed ID: 8148224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers.
    Apseloff G; Wilner KD; Gerber N
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):29S-33S. PubMed ID: 7547090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tenoxicam on renal function and the disposition of inulin and p-aminohippurate in healthy volunteers and patients with chronic renal failure.
    Freestone S; McAuslane JA; Prescott LF
    Br J Clin Pharmacol; 1991 Oct; 32(4):495-500. PubMed ID: 1958445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tenoxicam in healthy human volunteers.
    Heintz RC; Guentert TW; Enrico JF; Dubach UC; Brandt R; Jeunet FS
    Eur J Rheumatol Inflamm; 1984; 7(2):33-44. PubMed ID: 6336292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
    al-Ghamdi MS; al-Mohanna FA; al-Mustafa ZH; al-Saeed IS
    Eur J Clin Pharmacol; 1992; 43(2):197-9. PubMed ID: 1425878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fibrinolytic system during short-term treatment with tenoxicam.
    Jensen OH; Slot O; Ernst E
    Curr Med Res Opin; 1989; 11(8):518-22. PubMed ID: 2805772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.
    Hartmann D; Korn A; Komjati M; Heinz G; Haefelfinger P; Defoin R; Waldhäusl WK
    Br J Clin Pharmacol; 1990 Aug; 30(2):245-52. PubMed ID: 2119677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The countering of diazoxide-induced vasodilatation by tenoxicam in normal volunteers.
    Sommers DK; van Wyk M; Snyman JR
    Eur J Clin Pharmacol; 1994; 46(6):569-71. PubMed ID: 7995329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tenoxicam at different dosage regimes.
    Scaglione F; Demartini G; Dugnani S; Fraschini F; Triscari FA
    Farmaco; 1993 Sep; 48(9):1321-5. PubMed ID: 8259988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of concurrent aspirin upon plasma concentrations of tenoxicam.
    Day RO; Paull PD; Lam S; Swanson BR; Williams KM; Wade DN
    Br J Clin Pharmacol; 1988 Oct; 26(4):455-62. PubMed ID: 3190995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and multiple dose pharmacokinetics of tenoxicam in the elderly.
    Nilsen OG; Walstad RA; Eckert M; Heizmann P; Bückert A; Am T; Løge I; Unnvik J; Thue E
    Eur J Clin Pharmacol; 1988; 35(5):563-6. PubMed ID: 3266152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of cholestyramine on the elimination of tenoxicam and piroxicam.
    Guentert TW; Defoin R; Mosberg H
    Eur J Clin Pharmacol; 1988; 34(3):283-9. PubMed ID: 3260866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human serum albumin conformational changes as induced by tenoxicam and modified by simultaneous diazepam binding.
    Brée F; Urien S; Nguyen P; Tillement JP; Steiner A; Vallat-Molliet C; Testa B; Visy J; Simonyi M
    J Pharm Pharmacol; 1993 Dec; 45(12):1050-3. PubMed ID: 7908973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piroxicam and tenoxicam effects on ethanol-induced lipid peroxidation in brains of CD-1 male mice.
    Pérez-Tapia E; Saldaña-Balmori Y; Zentella-De Piña M; Ramíez-González MD; Piña-Garza E
    Proc West Pharmacol Soc; 1996; 39():77-9. PubMed ID: 8895975
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma tenoxicam concentrations after single and multiple oral doses.
    Crevoisier C; Heizmann P; Forgo I; Dubach UC
    Eur J Drug Metab Pharmacokinet; 1989; 14(1):23-7. PubMed ID: 2788089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
    Nilsen OG; Aasarød K; Widerøe TE; Guentert TW
    Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.